the NHS England Mounjaro NICE TA1026 rollout Multiple sclerosis cog-fog and remyelination ALS and motor neurone disease HGF/c-Met motor neuron protection and the Engensis (VM202) gene therapy translation Dihexa for Huntingtons Disease (AMT-130, WVE-003, Votoplam, 2026) However, none of these indications have progressed to clinical trials
If cagrilintide is approved, it would likely be priced in a similar range to other premium injectable weight-loss medicationsthough the exact number could go in either direction depending on insurance negotiations, patient assistance programs, and competitive dynamics with Zepbound and other competing medications
10.1007/s13562-016-0385-3 121 PeetersN.GuidotA.VailleauF.VallsM
MagnsdttirSRavcheevDde Crcy-LagardVThieleI
McWilliams DF, Walsh DA
Additionally, BPC 157 has shown promise in ameliorating neurological deficits after strokes in animal models, indicating a potential area for human clinical trials